https://www.selleckchem.com/products/pfi-3.html
Recent studies suggest an overrepresentation of promoter methylated tumors in females with wt glioblastoma (GBM) compared to males, with a subsequent better response to alkylating treatment. To reveal sex-bound associations that may have gone unnoticed in the original analysis, we re-analyzed two previously published clinical cohorts. One was the multicenter Nordic trial of elderly patients with GBM, randomizing patients into three different treatment arms, including 203 cases with known promoter methylation status. The other was a popula
Like
Comment
Share
